Business Context and Reporting Period
Company: Pluristem Therapeutics Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: February 21, 2013
Reporting Period: Single event date (February 21, 2013)
The registrant is a biopharmaceutical company incorporated in Nevada with principal executive offices in Haifa, Israel. This filing reports a specific regulatory milestone rather than periodic financial results.
Key Financial Metrics
This Form 8-K filing does not contain financial statements, revenue figures, profit data, cash flow information, margin analysis, debt levels, or liquidity metrics. The filing text does not provide a clear value for any financial indicators.
Material Changes
The material event reported is a regulatory designation granted by the U.S. Food and Drug Administration (FDA). On February 21, 2013, the FDA granted orphan drug status designation to the registrant's PLX cells for the treatment of aplastic anemia. This is a non-financial operational milestone.
Guidance, Outlook, and Risks
Management Commentary: The filing consists solely of the announcement of the FDA orphan status designation. No forward-looking guidance, financial outlook, or detailed management commentary is included in this document.
Risks and Contingencies: The filing does not explicitly list risks or contingencies. However, the context implies ongoing development efforts for the PLX cell therapy.
Key Facts for Investor Verification
- Verify the specific scope and benefits of the FDA orphan drug status granted to PLX cells for aplastic anemia.
- Confirm the current clinical development stage of the PLX cell therapy following this designation.
- Review subsequent filings (e.g., 10-K or 10-Q) for financial impact, as this 8-K contains no financial data.
- Monitor for updates on the regulatory pathway and potential market exclusivity periods associated with the orphan designation.